CSL (ASX:CSL) said the US Food and Drug Administration approved its hereditary angioedema drug, Andembry, for immediate launch in the US, according to a Tuesday Australian bourse filing.

The drug will be available through the company's third-party specialty pharmacy network before the end of the month, the filing said.